Page 14 - Packaged Retail News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS ANNOUNCEMENT WOULD BE UNLAWFUL. PLEASE SEE THE SECTION ENTITLED "DISCLAIMERS" AT THE END OF THIS ANNOUNCEMENT.   This announcement is an advertisement and does not constitute a prospectus and investors must subscribe for or purchase any shares referred to in this announcement only on the basis of information contained in the prospe...

Milestone for UK financial services as Bill receives Royal Assent The UK has taken an important first step in shaping its own financial services regulation outside the EU as the Financial Services Bill received Royal Assent today (29 April 2021). From: the Financial Services Bill has received Royal Assent and is now law represents major milestone in shaping a regulatory framework for UK financial services outside of the EU enhances competitiveness of the sector and ensures it continues to deliver for UK consumers and businesses The Bill – which is now an Act – will ensure the UK rema...

ANTITRUST AND COMPETITION The European Commission Accepts Commitments from a Pharma Company to Stop Its Excessive Prices On 15 May 2017, the European Commission (Commission) announced that it had opened formal proceedings to investigate whether a pharma company abused its dominant position by charging excessive prices for certain off-patent cancer medicines, in breach of EU antitrust rules. The Commission found that the pharma company has consistently earned very high profits from its sale of these cancer medicines in Europe, both in absolute terms and when compared with the profit levels of ...

Brussels Regulatory Brief: February 2021 Friday, March 12, 2021 The European Commission Accepts Commitments from a Pharma Company to Stop Its Excessive Prices On 15 May 2017, the European Commission (Commission) announced that it had opened formal proceedings to investigate whether a pharma company abused its dominant position by charging excessive prices for certain off-patent cancer medicines, in breach of EU antitrust rules. The Commission found that the pharma company has consistently earned very high profits from its sale of these cancer medicines in Europe, both in absolute te...

Operations: Swinging the axe at data management costs A not-for-profit industry ‘utility’ has demonstrated it can slash data management costs related to MiFID II. Alex Rolandi speaks to those involved, asking about the project’s future – and where the cost reductions are made. In December last year, The Investment and Savings Alliance (Tisa) launched a blockchain-powered tool aimed at reducing data management costs within the funds industry.  Since its inception, it has claimed to save firms involved in the project sums in excess of £100,000 (€115,600). Participants – which inc...